Letter to the editor: Adipose lipolysis is important for ethanol to induce fatty liver in the NIAAA murine model of chronic and binge ethanol feeding
Wenhao Luo, Yawen Wang, Ye Li, Taiping Zhang – 20 August 2022
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population
Prowpanga Udompap, Terry M. Therneau, Rachel E. Canning, Joanne T. Benson, Alina M. Allen – 20 August 2022
Early experiences with developing techniques for pure laparoscopic explant hepatectomy in living donor liver transplantation
Jane Chungyoon Kim, Suk Kyun Hong, Kwang‐Woong Lee, Sola Lee, Sanggyun Suh, Su young Hong, Eui Soo Han, YoungRok Choi, Nam‐Joon Yi, Kyung‐Suk Suh – 20 August 2022 – In recent years, laparoscopic techniques for liver resection or living donor hepatectomy have become common surgical methods. However, reports on laparoscopic surgeries for recipients are lacking. Our center has launched the minimally invasive living donor liver transplantation (LDLT) program in March 2020, which is led by two surgeons who are experienced in laparoscopic surgeries.
AIF1+CSF1R+MSCs, induced by TNF‐α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei – 20 August 2022
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Romain Donne, Amaia Lujambio – 20 August 2022 – The liver is the sixth most common site of primary cancer in humans and the fourth leading cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for 90% of liver cancers. HCC is a prevalent disease with a progression that is modulated by the immune system. Half of the patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib, as a first‐line therapy.
Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study
Marina Serper, David E. Kaplan, Tamar H. Taddei, Elliot B. Tapper, Jordana B. Cohen, Nadim Mahmud – 18 August 2022
Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation
Alix Demory, Jean‐Marie Péron, Julien Calderaro, Janick Selves, Fatima‐Zohra Mokrane, Giuliana Amaddeo, Valérie Paradis, Marianne Ziol, Olivier Sutter, Lorraine Blaise, Nathalie Ganne‐Carrié, Valérie Vilgrain, François Cauchy, Jessica Zucman‐Rossi, Maxime Ronot, Jean‐Charles Nault – 17 August 2022
Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review
Mounika Kanneganti, Jorge A. Marrero, Neehar D. Parikh, Fasiha Kanwal, Takeshi Yokoo, Mishal Mendiratta‐Lala, Nicole E. Rich, Purva Gopal, Amit G. Singal – 17 August 2022 – Patients with indeterminate liver nodules, classified as LR‐3 and LR‐4 observations per the Liver Imaging Reporting and Data System, are at risk of developing hepatocellular carcinoma (HCC), but risk estimates remain imprecise.
Domino liver transplantation: Don't slip in the pool
Kyle Soltys, George Mazariegos, John Bucuvalas – 17 August 2022
Outcomes of patients with acute liver failure listed for liver transplantation: A multicenter prospective cohort analysis
Constantine J. Karvellas, Thomas M. Leventhal, Jorge L. Rakela, Jingwen Zhang, Valerie Durkalski, K. Rajender Reddy, Robert J. Fontana, R. Todd Stravitz, John R. Lake, William M. Lee, Justin R. Parekh – 17 August 2022 – Liver transplantation (LT) is a life‐saving treatment for patients with acute liver failure (ALF). Currently, there are few detailed data regarding long‐term outcomes after LT for ALF.